Genprex licenses exclusive patent rights to Reqorsa for glioblastoma from UTHealth Houston

Genprex, Inc.

Exclusive patent license with UTHealth Houston grants Genprex commercial rights to Reqorsa for GBM.
Previous positive preclinical data (Oct 2024) showed Reqorsa reduced GBM cell viability and suppressed migration.
TUSC2 tumor suppressor identified as novel target for glioblastoma by UTHealth Houston researchers.
Company believes results support further in vivo evaluation in malignant glioma mouse models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.